Clinical Trial Search

Primary: Cmax: Maximum Observed Plasma Concentration for Alisertib and Drug-Related Material Following a Single Dose of [^14C]-Alisertib Oral Solution — 2183.3; 2606.7 nanomole…

Primary: Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2409021 — 48100 nanogram*hours per milliliter (ng*h/mL)

Primary: Number of Participants With Adverse Events — 4; 5; 5; 6 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 6; 5; 3; 3 Participants

Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2409021 — 2460; 2320; 2190; 2080 Nanogram per milliliter (ng/mL)

Primary: PINPOINT System Utility in Left Colectomy Surgery — 11; 128 Participants

Primary: Pharmacodynamics: Change From Baseline to Day 2 in 24-hour Insulin Dose — 1.85; 0.80; 7.69 insulin units — p=0.0542

Primary: Pharmacokinetics of Memantinol by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf)) — 1920.362; 2096.669 ng*h/mL — p=0.05

Primary: Safety: Severity Summary of Solicited and Unsolicited Adverse Events — 67; 92; 70; 3 AEs

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 29; 49; 11; 15 participants

Primary: Pharmacokinetics: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity [AUC(0-∞)] of LY2216684 in Cytochrome P450 (CYP)2C19 Extensive Metabolizers (EM)…

Primary: Urinary and Fecal Excretion of LY2603618 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered — 72.2; 11.0 percentage of total dose

Primary: Number of Participants With AEs — 0; 0; 2; 0 Participants

Primary: Plasma Pharmacokinetics of LY2603618: the Maximum Concentration of LY2603618 in the Plasma (Cmax) — 5950 nanograms/milliliter (ng/mL)

Primary: Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib: Cycle 2 Day 1 — 3552; 2712; 3238; 2305 nanogram*hour per…